{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:35Z","timestamp":1787020775284,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"crossref","award":["1330975"],"award-info":[{"award-number":["1330975"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-173223"],"award-info":[{"award-number":["PJT-173223"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2020-06822"],"award-info":[{"award-number":["RGPIN-2020-06822"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02299-4","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:53:28Z","timestamp":1779965608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kaiso modulates androgen receptor expression in triple-negative breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Stephanie","family":"Ali Fairbairn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindyann R.","family":"Lessey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Fanaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanad","family":"Adan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailaja","family":"Golamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet M.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2299_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40273-021-01121-7","volume":"40","author":"M Huang","year":"2022","unstructured":"Huang M, Haiderali A, Fox GE, Frederickson A, Cortes J, Fasching PA, et al. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. Pharmacoeconomics. 2022;40(5):519\u201358. https:\/\/doi.org\/10.1007\/s40273-021-01121-7","journal-title":"Rev PharmacoEconomics"},{"key":"2299_CR2","doi-asserted-by":"publisher","unstructured":"Orrantia\u2011Borunda E, Anchondo\u2011Nu\u00f1ez P, Acu\u00f1a\u2011Aguilar LE, G\u00f3mez\u2011Valles FO, Ram\u00edrez\u2011Valdespino CA. Subtypes of breast cancer. In: Mayrovitz HN, editor. Breast Cancer. Brisbane (AU): Exon Publications; 2022. Online first 22 Jun 2022. https:\/\/doi.org\/10.36255\/exon-publications-breast-cancer-subtypes","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"key":"2299_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"2299_CR4","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3390\/cancers17172938","volume":"17","author":"K Kannan","year":"2025","unstructured":"Kannan K, Srinivasan A, Kannan A, Ali N. The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. Cancers (Basel). 2025;17(17). https:\/\/doi.org\/10.3390\/cancers17172938","journal-title":"Cancers (Basel)"},{"key":"2299_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clbc.2024.03.001","volume":"24","author":"E Michaels","year":"2024","unstructured":"Michaels E, Chen N, Nanda R. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clin Breast Cancer. 2024;24(4):263\u201370. https:\/\/doi.org\/10.1016\/j.clbc.2024.03.001","journal-title":"Clin Breast Cancer"},{"key":"2299_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030526","author":"T Yang","year":"2023","unstructured":"Yang T, Li W, Huang T, Zhou J. Immunotherapy Targeting PD-1\/PD-L1 in Early-Stage Triple-Negative Breast Cancer. J Pers Med. 2023;13(3). https:\/\/doi.org\/10.3390\/jpm13030526","journal-title":"J Personalized Med"},{"key":"2299_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-025-00295-x","author":"A Essalihi","year":"2025","unstructured":"Essalihi A, Bouchra O, Khadiri K, Khadrouf Z, Karkouri M. Immunotherapy for triple-negative breast cancer: current trends and future prospects. J Egypt Natl Canc Inst. 2025;37(1):51. https:\/\/doi.org\/10.1186\/s43046-025-00295-x","journal-title":"J Egypt Natl Cancer Inst"},{"key":"2299_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03227-6","author":"A Jain","year":"2024","unstructured":"Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene. 2025;44(4):193\u2013207. https:\/\/doi.org\/10.1038\/s41388-024-03227-6","journal-title":"Oncogene Preprint at"},{"key":"2299_CR9","doi-asserted-by":"publisher","unstructured":"El Hejjioui B, Lamrabet S, Amrani Joutei S, Senhaji N, Bouhafa T, Malhouf MA, et al. New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics13111949","DOI":"10.3390\/diagnostics13111949"},{"key":"2299_CR10","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/j.clbc.2020.01.002","volume":"20","author":"M Xu","year":"2020","unstructured":"Xu M, Yuan Y, Yan P, Jiang J, Ma P, Niu X, et al. Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis. Clin Breast Cancer. 2020;20(4):e385\u2013e96. https:\/\/doi.org\/10.1016\/j.clbc.2020.01.002","journal-title":"Clin Breast Cancer"},{"key":"2299_CR11","doi-asserted-by":"publisher","unstructured":"Choupani E, Madjd Z, Saraygord-Afshari N, Kiani J, Hosseini A. Combination of androgen receptor inhibitor enzalutamide with the CDK4\/6 inhibitor ribociclib in triple negative breast cancer cells. PLoS One. 2022;17(12):e0279522. https:\/\/doi.org\/10.1371\/journal.pone.0279522","DOI":"10.1371\/journal.pone.0279522"},{"key":"2299_CR12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, et al. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018;36(9):884\u201390. https:\/\/doi.org\/10.1200\/JCO.2016.71.3495","journal-title":"J Clin Oncol"},{"key":"2299_CR13","doi-asserted-by":"crossref","unstructured":"Bonnefoi H, Lerebours F, Pulido M, Arnedos M, Tredan O, Dalenc F, et al. Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2025;26(3):355\u201366.","DOI":"10.1016\/S1470-2045(24)00737-X"},{"key":"2299_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01369-5","author":"S Bhattarai","year":"2020","unstructured":"Bhattarai S, Saini G, Gogineni K, Aneja R. Quadruple-negative breast cancer: novel implications for a new disease. Breast Cancer Res. 2020;22(1):127. https:\/\/doi.org\/10.1186\/s13058-020-01369-5 https:\/\/doi.org\/10.1186\/s13058-020-01369-5","journal-title":"Breast Cancer Res"},{"key":"2299_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020366","author":"A Qattan","year":"2022","unstructured":"Qattan A, Al-Tweigeri T, Suleman K. Translational Implications of Dysregulated Pathways and microRNA Regulation in Quadruple-Negative Breast Cancer. Biomedicines. 2022;10(2). https:\/\/doi.org\/10.3390\/biomedicines10020366","journal-title":"Biomedicines"},{"key":"2299_CR16","doi-asserted-by":"publisher","unstructured":"Oladeru O, Rajack F, Esnakula A, Naab TJ, Kanaan Y, Ricks-Santi L. Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans. Biomedicines. 2024;12(7). https:\/\/doi.org\/10.3390\/biomedicines12071522","DOI":"10.3390\/biomedicines12071522"},{"key":"2299_CR17","doi-asserted-by":"publisher","unstructured":"Davis M, Tripathi S, Hughley R, He Q, Bae S, Karanam B, et al. AR negative triple negative or \"quadruple negative\" breast cancers in African American women have an enriched basal and immune signature. PLoS One. 2018;13(6):e0196909. https:\/\/doi.org\/10.1371\/journal.pone.0196909","DOI":"10.1371\/journal.pone.0196909"},{"key":"2299_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184484","author":"N Jinna","year":"2022","unstructured":"Jinna N, Jovanovic-Talisman T, LaBarge M, Natarajan R, Kittles R, Sistrunk C, et al. Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention. Cancers (Basel). 2022;14(18). https:\/\/doi.org\/10.3390\/cancers14184484","journal-title":"Cancers"},{"key":"2299_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s10552-017-0955-2","volume":"28","author":"BI Bassey-Archibong","year":"2017","unstructured":"Bassey-Archibong BI, Hercules SM, Rayner LGA, Skeete DHA, Smith Connell SP, Brain I, et al. Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women. Cancer Causes Control. 2017;28(11):1295\u2013304. https:\/\/doi.org\/10.1007\/s10552-017-0955-2","journal-title":"Cancer Causes Control"},{"key":"2299_CR20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10552-022-01574-x","volume":"33","author":"SM Hercules","year":"2022","unstructured":"Hercules SM, Liu X, Bassey-Archibong BBI, Skeete DHA, Smith Connell S, Daramola A, et al. Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer. Cancer Causes Control. 2022;33(6):831\u201341. https:\/\/doi.org\/10.1007\/s10552-022-01574-x","journal-title":"Cancer Causes Control"},{"key":"2299_CR21","doi-asserted-by":"publisher","unstructured":"Martini R, Delpe P, Chu TR, Arora K, Lord B, Verma A, et al. African Ancestry-Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent. Cancer Discov. 2022;12(11):2530\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0138","DOI":"10.1158\/2159-8290.CD-22-0138"},{"key":"2299_CR22","doi-asserted-by":"publisher","unstructured":"Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers (Basel). 2018;10(12). https:\/\/doi.org\/10.3390\/cancers10120514","DOI":"10.3390\/cancers10120514"},{"key":"2299_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41588-024-01736-4","volume":"56","author":"G Jia","year":"2024","unstructured":"Jia G, Ping J, Guo X, Yang Y, Tao R, Li B, et al. Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction. Nat Genet. 2024;56(5):819\u201326. https:\/\/doi.org\/10.1038\/s41588-024-01736-4","journal-title":"Nat Genet"},{"key":"2299_CR24","doi-asserted-by":"publisher","unstructured":"Ahmed MSU, Lord BD, Adu Addai B, Singhal SK, Gardner K, Salam AB, et al. Immune Profile of Exosomes in African American Breast Cancer Patients Is Mediated by Kaiso\/THBS1\/CD47 Signaling. Cancers (Basel). 2023;15(8). https:\/\/doi.org\/10.3390\/cancers15082282","DOI":"10.3390\/cancers15082282"},{"key":"2299_CR25","doi-asserted-by":"publisher","unstructured":"Bocian A, Kedzierawski P, Kopczynski J, Wabik O, Wawruszak A, Kielbus M, et al. Kaiso Protein Expression Correlates with Overall Survival in TNBC Patients. J Clin Med. 2023;12(1). https:\/\/doi.org\/10.3390\/jcm12010370","DOI":"10.3390\/jcm12010370"},{"key":"2299_CR26","doi-asserted-by":"publisher","unstructured":"Bassey-Archibong BI, Rayner LG, Hercules SM, Aarts CW, Dvorkin-Gheva A, Bramson JL, et al. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death Dis. 2017;8(3):e2689. https:\/\/doi.org\/10.1038\/cddis.2017.92","DOI":"10.1038\/cddis.2017.92"},{"key":"2299_CR27","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.ajpath.2012.08.008","volume":"181","author":"J Jones","year":"2012","unstructured":"Jones J, Wang H, Zhou J, Hardy S, Turner T, Austin D, et al. Nuclear Kaiso indicates aggressive prostate cancers and promotes migration and invasiveness of prostate cancer cells. Am J Pathol. 2012;181(5):1836\u201346. https:\/\/doi.org\/10.1016\/j.ajpath.2012.08.008","journal-title":"Am J Pathol"},{"key":"2299_CR28","doi-asserted-by":"publisher","unstructured":"Daniel JM, Reynolds AB. The catenin p120(ctn) interacts with Kaiso, a novel BTB\/POZ domain zinc finger transcription factor. Mol Cell Biol. 1999;19(5):3614\u201323. https:\/\/doi.org\/10.1128\/MCB.19.5.3614","DOI":"10.1128\/MCB.19.5.3614"},{"key":"2299_CR29","doi-asserted-by":"publisher","unstructured":"Daniel JM, Spring CM, Crawford HC, Reynolds AB, Baig A. The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides. Nucleic Acids Res. 2002;30(13):2911\u20139 https:\/\/doi.org\/10.1093\/nar\/gkf398","DOI":"10.1093\/nar\/gkf398"},{"key":"2299_CR30","doi-asserted-by":"publisher","unstructured":"Donaldson NS, Pierre CC, Anstey MI, Robinson SC, Weerawardane SM, Daniel JM. Kaiso represses the cell cycle gene cyclin D1 via sequence-specific and methyl-CpG-dependent mechanisms. PLoS One. 2012;7(11):e50398. https:\/\/doi.org\/10.1371\/journal.pone.0050398","DOI":"10.1371\/journal.pone.0050398"},{"key":"2299_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.04.044","volume":"431","author":"A Abisoye-Ogunniyan","year":"2018","unstructured":"Abisoye-Ogunniyan A, Lin H, Ghebremedhin A, Salam AB, Karanam B, Theodore S, et al. Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c. Cancer Lett. 2018;431:1\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2018.04.044","journal-title":"Cancer Lett"},{"key":"2299_CR32","doi-asserted-by":"publisher","unstructured":"Luo W, Tripathi MK, Liu Q, Chen L, Cowan RW, Daniel JM, et al. Kaiso mediates transcription and RNA splicing in colorectal carcinoma: role of BRCA1 in the Kaiso enhanceosome. Open Biol. 2025;15(6):240329. https:\/\/doi.org\/10.1098\/rsob.240329","DOI":"10.1098\/rsob.240329"},{"key":"2299_CR33","doi-asserted-by":"publisher","unstructured":"Dai SD, Wang Y, Miao Y, Zhao Y, Zhang Y, Jiang GY, et al. Cytoplasmic Kaiso is associated with poor prognosis in non-small cell lung cancer. BMC Cancer. 2009;9:178. https:\/\/doi.org\/10.1186\/1471-2407-9-178","DOI":"10.1186\/1471-2407-9-178"},{"key":"2299_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.yexcr.2005.01.007","volume":"305","author":"CM Spring","year":"2005","unstructured":"Spring CM, Kelly KF, O'Kelly I, Graham M, Crawford HC, Daniel JM. The catenin p120ctn inhibits Kaiso-mediated transcriptional repression of the beta-catenin\/TCF target gene matrilysin. Exp Cell Res. 2005;305(2):253\u201365. https:\/\/doi.org\/10.1016\/j.yexcr.2005.01.007","journal-title":"Exp Cell Res"},{"key":"2299_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3892\/ol.2011.375","volume":"2","author":"S Vranic","year":"2011","unstructured":"Vranic S, Gatalica Z, Wang ZY. Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncol Lett. 2011;2(6):1131\u20137. https:\/\/doi.org\/10.3892\/ol.2011.375","journal-title":"Oncol Lett"},{"key":"2299_CR37","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367. https:\/\/doi.org\/10.1172\/JCI45014","journal-title":"J Clin Invest"},{"key":"2299_CR38","doi-asserted-by":"publisher","DOI":"10.3791\/52118","author":"DE Bauer","year":"2015","unstructured":"Bauer DE, Canver MC, Orkin SH. Generation of genomic deletions in mammalian cell lines via CRISPR\/Cas9. J Vis Exp. 2015(95):e52118. https:\/\/doi.org\/10.3791\/52118","journal-title":"J Visualized Experiments"},{"key":"2299_CR39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184\u20139 https:\/\/doi.org\/10.1038\/nbt.3437","journal-title":"Nat Biotechnol"},{"key":"2299_CR40","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308. https:\/\/doi.org\/10.1038\/nprot.2013.143","journal-title":"Nat Protoc"},{"key":"2299_CR41","unstructured":"John R. Cell Cloning by Serial Dilution in 96 Well Plates Protocol. Corning Incorporated Life Sciences. 2008."},{"key":"2299_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"key":"2299_CR43","doi-asserted-by":"publisher","unstructured":"Heath AP, Ferretti V, Agrawal S, An M, Angelakos JC, Arya R, et al. The NCI Genomic Data Commons. Nat Genet. 2021;53(3):257\u201362 https:\/\/doi.org\/10.1038\/s41588-021-00791-5","DOI":"10.1038\/s41588-021-00791-5"},{"key":"2299_CR44","doi-asserted-by":"publisher","unstructured":"Nagy A, Munkacsy G, Gyorffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021;11(1):6047. https:\/\/doi.org\/10.1038\/s41598-021-84787-5","DOI":"10.1038\/s41598-021-84787-5"},{"key":"2299_CR45","doi-asserted-by":"publisher","unstructured":"Bassey-Archibong BI, Kwiecien JM, Milosavljevic SB, Hallett RM, Rayner LG, Erb MJ, et al. Kaiso depletion attenuates transforming growth factor-beta signaling and metastatic activity of triple-negative breast cancer cells. Oncogenesis. 2016;5(3):e208. https:\/\/doi.org\/10.1038\/oncsis.2016.17","DOI":"10.1038\/oncsis.2016.17"},{"key":"2299_CR46","doi-asserted-by":"publisher","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135. https:\/\/doi.org\/10.1038\/nmeth.2089","DOI":"10.1038\/nmeth.2089"},{"key":"2299_CR47","doi-asserted-by":"publisher","unstructured":"Sahoo B, Pinnix Z, Zelikovsky A. Deep Learning Reveals Biological Basis of Racial Disparities in Quadruple-Negative Breast Cancer. International Symposium on Bioinformatics Research and Applications: Springer, Singapore; 2023. p. 498\u2013508 https:\/\/doi.org\/10.1007\/978-981-99-7074-2_40","DOI":"10.1007\/978-981-99-7074-2_40"},{"key":"2299_CR49","doi-asserted-by":"publisher","unstructured":"Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One.2016;11(6):e0157368. https:\/\/doi.org\/10.1371\/journal.pone.0157368","DOI":"10.1371\/journal.pone.0157368"},{"key":"2299_CR50","doi-asserted-by":"publisher","first-page":"D51","DOI":"10.1093\/nar\/gkw1069","volume":"45","author":"R Dreos","year":"2017","unstructured":"Dreos R, Ambrosini G, Groux R, Cavin Perier R, Bucher P. The eukaryotic promoter database in its 30th year: focus on non-vertebrate organisms. Nucleic Acids Res. 2017;45(D1):D51\u2013D5. https:\/\/doi.org\/10.1093\/nar\/gkw1069","journal-title":"Nucleic Acids Res"},{"key":"2299_CR51","doi-asserted-by":"publisher","unstructured":"Monaco ME. ACSL4: biomarker, mediator and target in quadruple negative breast cancer. Oncotarget. 2023;14:563\u201375 https:\/\/doi.org\/10.18632\/oncotarget.28453","DOI":"10.18632\/oncotarget.28453"},{"key":"2299_CR52","unstructured":"Zhang X. Regulation of long-chain fatty acyl-coa synthase 4 by androgen receptor in prostate cancer. Master's Thesis, University of Georgia, 2018."},{"key":"2299_CR53","doi-asserted-by":"publisher","unstructured":"Hou J, Jiang C, Wen X, Li C, Xiong S, Yue T, et al. ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics. Front Pharmacol. 2022;13:949863 https:\/\/doi.org\/10.3389\/fphar.2022.949863","DOI":"10.3389\/fphar.2022.949863"},{"key":"2299_CR54","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u201352. https:\/\/doi.org\/10.1038\/nature10983","journal-title":"Nature"},{"key":"2299_CR55","doi-asserted-by":"publisher","unstructured":"Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479 https:\/\/doi.org\/10.1038\/ncomms11479","DOI":"10.1038\/ncomms11479"},{"key":"2299_CR56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134 https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095","journal-title":"Cancer Discov"},{"key":"2299_CR57","doi-asserted-by":"publisher","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491 https:\/\/doi.org\/10.3389\/fonc.2024.1405491","DOI":"10.3389\/fonc.2024.1405491"},{"key":"2299_CR58","doi-asserted-by":"publisher","unstructured":"Rajagopal PS, Reid S, Fan R, Venton L, Weidner A, Roberson ML, et al. Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer. NPJ Breast Cancer. 2025;11(1):28. https:\/\/doi.org\/10.1038\/s41523-025-00731-0","DOI":"10.1038\/s41523-025-00731-0"},{"key":"2299_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02322-y","author":"S Yao","year":"2025","unstructured":"Yao S, Wei L, Hu Q, Liu S, Manojlovic Z, Fiorica PN, et al. Mutational landscape of triple-negative breast cancer in African American women. Nat Genet. 2025;57(9):2166\u201376. https:\/\/doi.org\/10.1038\/s41588-025-02322-y","journal-title":"Nat Genet"},{"key":"2299_CR60","doi-asserted-by":"publisher","unstructured":"Liu Y, Jiang X, Jing D, Lin Y, Gao R, Zhao Q, et al. ACSL4 knockdown inhibits colorectal cancer progression through stimulating anti-tumor immunity. Neoplasia. 2025;67:101194. https:\/\/doi.org\/10.1016\/j.neo.2025.101194","DOI":"10.1016\/j.neo.2025.101194"},{"key":"2299_CR61","doi-asserted-by":"publisher","unstructured":"Lam IH, Chan CI, Han M, Li L, Yu HH. ACSL4 mediates inflammatory bowel disease and contributes to LPS-induced intestinal epithelial cell dysfunction by activating ferroptosis and inflammation. Open Med (Wars). 2024;19(1):20240993. https:\/\/doi.org\/10.1515\/med-2024-0993","DOI":"10.1515\/med-2024-0993"},{"key":"2299_CR62","doi-asserted-by":"publisher","unstructured":"Wu X, Deng F, Li Y, Daniels G, Du X, Ren Q, et al. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance. Oncotarget. 2015;6(42):44849\u201363 https:\/\/doi.org\/10.1016\/j.bcp.2024.116206","DOI":"10.1016\/j.bcp.2024.116206"},{"key":"2299_CR63","doi-asserted-by":"publisher","unstructured":"Wu D, Zuo Z, Sun X, Li X, Yin F, Yin W. ACSL4 promotes malignant progression of Hepatocellular carcinoma by targeting PAK2 transcription. Biochem Pharmacol. 2024;224:116206. https:\/\/doi.org\/10.1016\/j.bcp.2024.116206","DOI":"10.1016\/j.bcp.2024.116206"},{"key":"2299_CR64","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s00018-020-03679-5","volume":"78","author":"AF Castillo","year":"2021","unstructured":"Castillo AF, Orlando UD, Maloberti PM, Prada JG, Dattilo MA, Solano AR, et al. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis. Cell Mol Life Sci. 2021;78(6):2893\u2013910. https:\/\/doi.org\/10.1007\/s00018-020-03679-5","journal-title":"Cell Mol Life Sci"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02299-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:55:37Z","timestamp":1782395737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02299-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were done in accordance with the ethical standards of McMaster University, LUTH and QEH and Ethics approval #15826.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Funding for this study was provided by CIHR (Grant # PJT-173223) and NSERC (Grant #RGPIN-2020-06822) to JMD and the Cancer Research Society (Grant #1330975) to SAF.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}],"article-number":"116"}}